New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study

• Conditions: Alzheimer Disease, Late Onset

• Registration Number: NCT01773915
• Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Brief Summary

Alzheimer's disease (AD) is the most common neurodegenerative disorder afflicting the elderly. Currently, some biochemical tests performed on Cerebrospinal Fluid (CSF) samples have demonstrated to discriminate to some extend between AD and non-AD individuals based on the levels of tau, phospho-tau or Aβ42. We aim to investigate newly identified proteins whose levels increase during the Braak Stages of AD that are accessible in other body fluids such as blood, urine or saliva. The detection of these proteins would allow performing simple tests in case its levels were confirmed to be associated with the AD pathology.

Detailed Description

We do not desire to provide a more extensive description

Study Timeline

• Study Start: 2012-12
• Study First Submitted: 2012-12-26
• Status Verified: 2013-01
• Study First Submitted QC: 2013-01-18
• Study First Posted: 2013-01-23
• Primary Completion: 2014-01
• Last Update Submitted: 2014-01-13
• Last Update Posted: 2014-01-14
• Study Completion: 2014-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• mild to moderate AD

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Differences in blood, saliva and urine protein levels in patients with Alzheimer's Disease versus healthy controls.	Up to 1 year	Protein levels will be measured by classical immunoblotting blot analysis and quantified; Classical statistical analyses will be performed in order to detect any significant differences.

Trial Locations

Locations (1)

UZ Leuven; 🇧🇪 Leuven, Belgium